Statements (63)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:accessories |
pharmaceutical distributors
|
| gptkbp:administration_duration |
over 60 minutes
|
| gptkbp:approves |
November 2020
|
| gptkbp:availability |
prescription only
|
| gptkbp:average_temperature |
2 to 8 degrees Celsius
|
| gptkbp:clinical_trial |
Phase 2
BLAZE-1 showed reduced viral load |
| gptkbp:clinical_use |
outpatient treatment
used in outpatient settings |
| gptkbp:community_health |
part of pandemic response
|
| gptkbp:contraindication |
hypersensitivity to the drug
|
| gptkbp:developed_by |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:dosage_form |
solution for infusion
|
| gptkbp:drug_interactions |
none significant reported
|
| gptkbp:duration |
single dose administration
|
| gptkbp:effective_date |
Emergency Use Authorization
|
| gptkbp:eligibility |
positive COVID-19 test
|
| gptkbp:events |
monitor for side effects
|
| gptkbp:funding |
government and private sources
|
| https://www.w3.org/2000/01/rdf-schema#label |
Bamlanivimab injection
|
| gptkbp:indication |
mild to moderate COVID-19
|
| gptkbp:is_a_guide_for |
consider for high-risk patients
|
| gptkbp:is_effective_against |
reduces hospitalization rates
|
| gptkbp:is_monitored_by |
vital signs during infusion
|
| gptkbp:manufacturer |
gptkb:Eli_Lilly
|
| gptkbp:market |
monitoring for long-term effects
|
| gptkbp:marketed_as |
gptkb:Bamlanivimab
|
| gptkbp:mechanism_of_action |
neutralizes the virus
|
| gptkbp:patient_education |
informed consent required
|
| gptkbp:patient_population |
adults and pediatric patients
|
| gptkbp:pharmaceutical_formulation |
sterile solution
|
| gptkbp:pharmacokinetics |
half-life of approximately 15 days
|
| gptkbp:price |
varies by provider
|
| gptkbp:provides_guidance_on |
CDC recommendations
follow local health authority guidelines hospital or outpatient clinic updated regularly based on evidence |
| gptkbp:recruitment |
based on risk factors
|
| gptkbp:regulatory_compliance |
FDA approved
|
| gptkbp:research |
ongoing studies for variants
|
| gptkbp:research_focus |
COVID-19 treatment efficacy
|
| gptkbp:route_of_administration |
intravenous
IV infusion |
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:safety_measures |
recommended during treatment
|
| gptkbp:side_effect |
fatigue
headache nausea diarrhea anaphylaxis infusion reactions |
| gptkbp:supply_chain |
critical for distribution
cold chain required |
| gptkbp:supply_limitations |
availability may vary
|
| gptkbp:targets |
SARS-Co V-2 virus
|
| gptkbp:treatment |
gptkb:Etesevimab
improved recovery time |
| gptkbp:type_of_insurance |
may be covered by health plans
|
| gptkbp:used_for |
treatment of COVID-19
|
| gptkbp:bfsParent |
gptkb:Bamlanivimab
|
| gptkbp:bfsLayer |
6
|